BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11115440)

  • 21. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
    DeAbate CA; Henry D; Bensch G; Jubran A; Chodosh S; Harper L; Tipping D; Talbot GH
    Chest; 1998 Jul; 114(1):120-30. PubMed ID: 9674458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temafloxacin in acute purulent exacerbations of chronic bronchitis.
    Davies BI; Maesen FP; Gubbelmans HL; Cremers HM
    J Antimicrob Chemother; 1990 Aug; 26(2):237-46. PubMed ID: 2120178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.
    Anzueto A; Gotfried M; Wikler MA; Russo R; Nicholson SC
    Clin Ther; 2002 Jun; 24(6):906-17. PubMed ID: 12117081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
    Cazzola M; Di Perna F; Boveri B; Di Marco F; Diamare F; Centanni S
    J Chemother; 2000 Jun; 12(3):216-22. PubMed ID: 10877516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis.
    Wolter JM; Rodwell RL; Bowler SD; McCormack JG
    Clin Diagn Lab Immunol; 1999 Mar; 6(2):260-5. PubMed ID: 10066664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gram stain and culture of morning and 24 h sputum in the diagnosis of bacterial exacerbation of chronic bronchitis: a dogma disputed.
    Medici TC; von Graevenitz A; Shang H; Böhni E; Wall M
    Eur Respir J; 1988 Dec; 1(10):923-8. PubMed ID: 2465180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD.
    Wilkinson TMA; Aris E; Bourne S; Clarke SC; Peeters M; Pascal TG; Schoonbroodt S; Tuck AC; Kim V; Ostridge K; Staples KJ; Williams N; Williams A; Wootton S; Devaster JM;
    Thorax; 2017 Oct; 72(10):919-927. PubMed ID: 28432209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations.
    Qvarfordt I; Riise GC; Andersson BA; Larsson S
    Respir Med; 2000 Sep; 94(9):881-7. PubMed ID: 11001080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease.
    Bresser P; Out TA; van Alphen L; Jansen HM; Lutter R
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):947-52. PubMed ID: 10988111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study.
    Swanson RN; Lainez-Ventosilla A; De Salvo MC; Dunne MW; Amsden GW
    Treat Respir Med; 2005; 4(1):31-9. PubMed ID: 15725048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of acute exacerbations of chronic bronchitis: antibiotic therapy.
    Anzueto A
    Semin Respir Crit Care Med; 2000; 21(2):97-106. PubMed ID: 16088723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibiotic therapy for exacerbation].
    Dalhoff K; Kothe H
    Internist (Berl); 2006 Sep; 47(9):908, 910-2, 914-6. PubMed ID: 16855849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function.
    Eller J; Ede A; Schaberg T; Niederman MS; Mauch H; Lode H
    Chest; 1998 Jun; 113(6):1542-8. PubMed ID: 9631791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute bacterial exacerbations in bronchitis and asthma.
    Chodosh S
    Am J Med; 1987 Apr; 82(4A):154-63. PubMed ID: 3578322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.
    Patel IS; Seemungal TA; Wilks M; Lloyd-Owen SJ; Donaldson GC; Wedzicha JA
    Thorax; 2002 Sep; 57(9):759-64. PubMed ID: 12200518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
    Casellas JM; Gilardoni M; Tome G; Goldberg M; Ivanovic S; Orduna M; Dolmann A; Ascoli M; Ariza H; Montero JM
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis.
    Paster RZ; McAdoo MA; Keyserling CH; Nemeth MA; Tack KJ; Griffin TJ
    Int J Clin Pract; 2000 Jun; 54(5):293-9. PubMed ID: 10954955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S; Breton J; Wynne B
    Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.